Switch theme
Sign up to access all valuation multiples
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
1999
n/a
LTM Revenue $3.8B
LTM EBITDA $442M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DaShenLin Pharmaceutical has a last 12-month revenue (LTM) of $3.8B and a last 12-month EBITDA of $442M.
In the most recent fiscal year, DaShenLin Pharmaceutical achieved revenue of $3.7B and an EBITDA of $420M.
DaShenLin Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DaShenLin Pharmaceutical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.8B | XXX | $3.7B | XXX | XXX | XXX |
| Gross Profit | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| Gross Margin | 35% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $442M | XXX | $420M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBIT | $216M | XXX | $224M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $140M | XXX | $127M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, DaShenLin Pharmaceutical's stock price is CNY 17 (or $2).
DaShenLin Pharmaceutical has current market cap of CNY 19.8B (or $2.8B), and EV of CNY 19.9B (or $2.8B).
See DaShenLin Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.8B | XXX | XXX | XXX | XXX | $0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, DaShenLin Pharmaceutical has market cap of $2.8B and EV of $2.8B.
DaShenLin Pharmaceutical's trades at 0.8x EV/Revenue multiple, and 6.6x EV/EBITDA.
Equity research analysts estimate DaShenLin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DaShenLin Pharmaceutical has a P/E ratio of 19.6x.
See valuation multiples for DaShenLin Pharmaceutical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | 6.2x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBIT | 12.8x | XXX | 12.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 19.6x | XXX | 21.7x | XXX | XXX | XXX |
| EV/FCF | 11.8x | XXX | 12.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDaShenLin Pharmaceutical's last 12 month revenue growth is 11%
DaShenLin Pharmaceutical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
DaShenLin Pharmaceutical's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DaShenLin Pharmaceutical's rule of X is 39% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DaShenLin Pharmaceutical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 39% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DaShenLin Pharmaceutical acquired XXX companies to date.
Last acquisition by DaShenLin Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . DaShenLin Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DaShenLin Pharmaceutical founded? | DaShenLin Pharmaceutical was founded in 1999. |
| Where is DaShenLin Pharmaceutical headquartered? | DaShenLin Pharmaceutical is headquartered in China. |
| Is DaShenLin Pharmaceutical publicy listed? | Yes, DaShenLin Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical trades under 603233 ticker. |
| When did DaShenLin Pharmaceutical go public? | DaShenLin Pharmaceutical went public in 2017. |
| Who are competitors of DaShenLin Pharmaceutical? | Similar companies to DaShenLin Pharmaceutical include e.g. MedPlus India, SC Ropharma, Pague Menos, Droga Raia. |
| What is the current market cap of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's current market cap is $2.8B |
| What is the current revenue of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months revenue is $3.8B. |
| What is the current revenue growth of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of DaShenLin Pharmaceutical? | Current revenue multiple of DaShenLin Pharmaceutical is 0.7x. |
| Is DaShenLin Pharmaceutical profitable? | Yes, DaShenLin Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months EBITDA is $442M. |
| What is DaShenLin Pharmaceutical's EBITDA margin? | DaShenLin Pharmaceutical's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of DaShenLin Pharmaceutical? | Current EBITDA multiple of DaShenLin Pharmaceutical is 6.2x. |
| What is the current FCF of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months FCF is $234M. |
| What is DaShenLin Pharmaceutical's FCF margin? | DaShenLin Pharmaceutical's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of DaShenLin Pharmaceutical? | Current FCF multiple of DaShenLin Pharmaceutical is 11.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
